Max Neeman expands its presence in Asia Pacific region

Max Neeman International now has a larger Asia-Pacific footprint with new presence and capabilities in neighbouring countries of Bangladesh, Sri Lanka and Malaysia


Increased global presence of Max Neeman

Having established itself in India, Europe and North America, the leading Indian CRO, Max Neeman International has increased its global presence by expanding in Bangladesh, Sri Lanka and Malaysia. The additional locations, enable Max Neeman to enroll one hundred percent of subjects for a sponsor's benefit in terms of quality, time and cost control.

According to the company, these Asia-Pacific countries are ideal locations for clinical trials due to access to many treatment naïve patients across a variety of disease areas, local medical expertise and infrastructure, standard of care that is comparable to developed countries and, regulatory ease. Sponsors will have increased access to an additional 200M+ patient population while in close proximity to the Max Neeman organization. This scenario coupled with a high number of English speaking and well-qualified physicians provides the same advantages as India offers both in terms of quality and cost-effectiveness for conducting clinical trials.

In Bangladesh, Max Neeman has well established contacts with the leading investigators and physicians of the country and is capable of running the project end to end. The company's in-house Regulatory team handles the regulatory submissions and Ethics Committee [EC] submissions at Bangladesh Medical Research Council (BMRC); the regulatory body for governing clinical trials in Bangladesh. Also for overall project management of the study, Max Neeman CRAs and PMs will manage site selection, qualification, and monitoring of all sites, to ensure that the study is conducted per ICH GCP and local regulatory guidelines.

Again in Sri Lanka and Malaysia, the overall project management for the study will also be carried out by Max Neeman's operations team for site qualification and monitoring of sites to ensure the study is being conducted in compliance with ICH GCP and local regulatory guidelines.

"Max Neeman's additional Asia-Pac presence allows us an access to these geographies and hence the subjects. All countries have Regulatory requirements; India is no different and while it may take some additional time to approval, Max Neeman will be ready to start and Sponsors can rest assure that faster recruitment will make up the time" , said COO Dr Renu Razdan.

For over a decade, the company has provided clinical research services for the successful conduct of Phase II-IV drug and device trials to pharmaceutical, biotech, medical device and nutraceutical companies in compliance with ICH GCP standards. 'Max Neeman' is ISO 9001:2008 certified for monitoring, site management and data management with over 400 employees, 200 active sites in various therapeutic areas and 304 trials awarded to date.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email